


Alosetron ((Z)-2-butenedioate)

Chemical Properties

CAS No. :	122852-43-1
Formula:	C ₂₁ H ₂₂ N ₄ O ₅
Molecular Weight:	410.42
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Alosetron (GR 68755) (Z)-2-butenedioate is a Serotonin 5-HT ₃ receptor antagonist used for the treatment of irritable bowel syndrome.
Targets(IC ₅₀)	Others,5-HT Receptor
In vitro	Alosetron has an antagonist action on the 5-HT ₃ receptors of the enteric nervous system of the gastrointestinal tract. Since stimulation of 5-HT ₃ receptors is positively correlated with gastrointestinal motility, alosetron's 5-HT ₃ antagonism slows the movement of fecal matter through the large intestine, increasing the extent to which water is absorbed, and decreasing the moisture and volume of the remaining waste products.

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.4365 mL	12.1826 mL	24.3653 mL
5 mM	0.4873 mL	2.4365 mL	4.8731 mL
10 mM	0.2437 mL	1.2183 mL	2.4365 mL
50 mM	0.0487 mL	0.2437 mL	0.4873 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Bleser S. Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes. *Curr Med Res Opin.* 2011 Mar;27(3):503-12.
- Lucak SL. Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. *Therap Adv Gastroenterol.* 2010 May;3(3):165-72.
- Lewis JH. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. *Expert Rev Gastroenterol Hepatol.* 2010 Feb;4(1):13-29.
- Painsipp E, Shahbazian A, Holzer P. Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats. *Br J Pharmacol.* 2009 Nov;158(5):1210-26.
- Targeting the 5-HT₃ receptor in the treatment of irritable bowel syndrome By Spiller, Robin C. From *Current Opinion in Pharmacology* (2011), 11(1), 68-74.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481